3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
OTHER
3
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Breast Neoplasms
13
Glioblastoma
10
Glioma
7
Astrocytoma
6
Carcinoma, Non-Small-Cell Lung
5
Urinary Bladder Neoplasms
4
Neoplasms
4
Brain Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Stomach Neoplasms
2
Recurrence
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Melanoma
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Seroma
1
Rectal Neoplasms
1
Pleural Neoplasms
1
Pleural Effusion, Malignant
1
Pleural Effusion
1
Pleural Diseases
1
Patient Preference
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Inflammatory Breast Neoplasms
1
Interventions
pembrolizumab
15
Nivolumab
10
Ipilimumab
7
cemiplimab
6
dabrafenib
4
binimetinib
4
Dacarbazine
4
trametinib
3
encorafenib
3
Drug Therapy
3
Allovectin-7
3
zanolimumab
2
talabostat
2
lifileucel
2
aldesleukin
2
Vemurafenib
2
Tablets
2
Semaxinib
2
Intravital Microscopy
2
Interleukin-2
2
Fluorouracil
2
vitespin
1
veliparib
1
varlilumab
1
tozuleristide
1
tin etiopurpurin
1
tilsotolimod
1
spartalizumab
1
sotigalimab
1
sonidegib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Skin Neoplasms
×
Surgical Procedures, Operative
×
Clear all
NCT06295809
2026-05-08
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3
Terminated
46 enrolled